AlloVir (Nasdaq:ALVR) - Prezzo delle azioni, notizie e analisi

ALVR Panoramica delle azioni

Allovir, Inc. è un'azienda di terapie cellulari in fase clinica, impegnata nella ricerca e nello sviluppo di terapie con cellule T allogeniche specifiche per più virus (VST) per la prevenzione e il trattamento di malattie virali devastanti. Maggiori dettagli

ALVR analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Prezzo delle azioni volatile negli ultimi 3 mesi

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

+ 1 più rischio

AlloVir, Inc. Concorrenti

Cue Biopharma

NasdaqCM:CUE

US$69.1m

Spero Therapeutics

NasdaqGS:SPRO

US$61.6m

Cellectar Biosciences

NasdaqCM:CLRB

US$64.4m

BioAtla

NasdaqGM:BCAB

US$75.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per AlloVir
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.54
Massimo di 52 settimane	US$2.49
Minimo di 52 settimane	US$0.51
Beta	0.74
1Variazione di 1 mese	-36.70%
Variazione a 3 mesi	-30.17%
Variazione di 1 anno	-69.62%
3Variazione a 3 anni	-96.87%
Variazione a 5 anni	n/a
Variazione dall'IPO	-97.87%

Notizie e aggiornamenti recenti

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Rendimenti per gli azionisti

	ALVR	US Biotechs	US Mercato
7D	-5.1%	4.0%	2.0%
1Y	-69.6%	18.0%	32.4%

Ritorno vs Industria: ALVR ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18 % nell'ultimo anno.

Rendimento vs Mercato: ALVR ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	15.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ALVR è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 15% ) di ALVR è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	8	Diana Brainard	www.allovir.com

Allovir, Inc. è un'azienda di terapie cellulari in fase clinica, impegnata nella ricerca e nello sviluppo di terapie allogeniche di cellule T multivirus specifiche (VST) per prevenire e curare devastanti malattie associate ai virus. Il prodotto di punta dell'azienda è posoleucel, una terapia VST allogenica e non disponibile, per il trattamento del virus BK, del citomegalovirus, dell'adenovirus, del virus di Epstein-Barr, dell'herpesvirus umano 6 e del virus JC. I suoi prodotti candidati allo sviluppo preclinico e clinico includono ALVR106 per il trattamento del virus respiratorio sinciziale, dell'influenza, del virus parainfluenzale e del metapneumovirus umano; ALVR109 per il trattamento della SARS-CoV-2 e del COVID-19; ALVR107 per il trattamento dell'epatite B e ALVR108.

AlloVir, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di AlloVir con la sua capitalizzazione di mercato?
ALVR statistiche fondamentali
Capitalizzazione di mercato	US$61.19m
Guadagni(TTM)	-US$100.20m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.6x

Rapporto P/E

ALVR è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ALVR Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$100.20m
Guadagni	-US$100.20m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.88
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ALVR nel lungo periodo?

Vedi performance storica e confronto

ALVR Panoramica delle azioni

Analisi del rischio

AlloVir, Inc. Concorrenti

NasdaqCM:CUE

US$69.1m

NasdaqGS:SPRO

US$61.6m

NasdaqCM:CLRB

US$64.4m

NasdaqGM:BCAB

US$75.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Recent updates

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock